The quarter cleared published expectations, led by sales rather than earnings. Net sales were $2.177 billion, above the published consensus range of roughly $2.13 billion-$2.16 billion, while adjusted EPS of $2.07 exceeded the roughly $2.01-$2.03 expectation. The more consequential update is the full-year revenue outlook: the midpoint for organic constant-currency growth rose 75 basis points to 2.75%, signaling management sees better underlying demand than it did three months ago. (Geographic and Product Category Sales; Financial Guidance)
| Metric | Q2 2026 actual | Q2 2025 / published expectation | Read-through |
|---|---|---|---|
| Net sales | $2.177B | $2.077B; consensus roughly $2.13B-$2.16B | 4.8% reported growth; modest revenue beat (Condensed Consolidated Statements of Earnings) |
| Organic constant-currency sales growth | 4.0% | — | Above the updated full-year 2.25%-3.25% outlook (Sales-change reconciliation; Financial Guidance) |
| Adjusted diluted EPS | $2.07 | $2.07; consensus roughly $2.01-$2.03 | Small beat, but no year-over-year adjusted EPS growth (Reconciliation of Reported to Adjusted Results) |
| Adjusted operating margin | 25.7% | 27.8% | Down 210 basis points despite the sales increase (Adjusted Operating Profit & Margin) |
| Full-year organic constant-currency growth outlook | 2.25%-3.25% | 1.0%-3.0% previously | Midpoint raised 75 basis points (Financial Guidance) |
| Full-year adjusted EPS outlook | $8.47-$8.59 | $8.40-$8.55 previously | Midpoint raised $0.06, a comparatively modest lift (Financial Guidance) |
| Q2 free cash flow | $308.3M | $247.7M | Cash conversion improved year over year (Free Cash Flow reconciliation) |
The guidance raise makes this better than a one-quarter beat. Reported revenue growth guidance moved to 3.9%-4.9% from 2.5%-4.5%, and constant-currency growth moved to 3.4%-4.4% from 2.0%-4.0%. Because the organic outlook also rose, the improvement is not merely currency or the Paragon 28 acquisition contribution. (Financial Guidance)
The limitation is profitability: stronger sales are not yet producing operating leverage. Adjusted operating profit fell to $559.7 million from $578.5 million, and adjusted margin contracted to 25.7% from 27.8%. Flat adjusted EPS therefore understates neither a collapse nor a clean earnings acceleration: the company delivered more revenue but less adjusted operating profit, with the quarterly EPS beat comparatively narrow. (Adjusted Operating Profit & Margin; Reconciliation of Reported to Adjusted Results)
Growth was uneven beneath the headline. Hips grew 5.1% and Technology & Data, Bone Cement and Surgical grew 21.5% organically in constant currency, while total Knees were essentially flat at 0.1%; international Knees declined 1.5%. That mix supports the raised outlook, but it also shows the core knee franchise was not the source of the quarter's upside. (Geographic and Product Category Sales)
Cash flow and buybacks add support, though they do not solve the margin issue. Second-quarter free cash flow increased 24% to $308.3 million, and the company lifted planned 2026 repurchases to up to $1 billion. It had already repurchased $500.8 million of stock in the first half, while net debt edged up to $7.069 billion as cash declined. (Free Cash Flow reconciliation; Condensed Consolidated Statements of Cash Flows; Debt to Net Debt reconciliation)
Read the original 8-K on SEC EDGAR ↗